Waiting for microbiologic data to direct therapy against nosocomial infections in febrile surgical patients: are outcomes worsened?
OBJECTIVE
Allowing adequate time for laboratory and culture results before initial treatment may be associated with a worse outcome in nosocomial infections.


METHODS
Cohort study of all episodes of nosocomial infection from December 10, 1996, to October 28, 1998.


METHODS
Surgical services at a university hospital.


METHODS
In surgical patients presenting with fever, 372 episodes of nosocomial infection were evaluated. Nosocomial infections were divided by time from fever to intervention (< or =12, 13-24, and >24 hours). These groups were subdivided by Acute Physiology and Chronic Health Evaluation II (APACHE II) scores into low (< or =10 [n = 114]), moderate (11-20 [n = 169]), and high severity of illness (>20 [n = 89]). Pneumonia and bloodstream infections were divided by APACHE II scores into low (< or =15 [n = 55 and n = 56, respectively]) or high severity of illness (>15 [n = 84 and n = 77, respectively]).


METHODS
Mortality, length of stay.


RESULTS
No difference in outcome was seen between different time intervals from fever to intervention for nosocomial infections in patients with APACHE II scores of no more than 10. Patients treated more than 24 hours after fever were significantly younger than those treated at no more than 12 and 13 to 24 hours with APACHE II scores of 11 to 20 (P<.05) and more than 20 (P<.05). Mortality and length of stay for patients treated at later time intervals were comparable with those of patients treated earlier with similar APACHE II scores. There was no difference in outcome for patients with pneumonia or bloodstream infection.


CONCLUSIONS
Episodes of infection in which treatment was withheld until initial microbiologic data were available (24 hours) did not have worse outcomes compared with those treated earlier. Waiting for laboratory and culture results to direct antibiotic therapy for nosocomial infections does not appear harmful and may be potentially beneficial.
Pelletier
S J
SJ
Department of Surgery, University of Virginia Health Sciences Center, Charlottesville 22908, USA. sjp7t@virginia.edu
Crabtree
T D
TD
Gleason
T G
TG
Banas
L E
LE
Patel
S R
SR
Pruett
T L
TL
Sawyer
R G
RG
D018806:APACHE; D016470:Bacteremia / Q000188:drug therapy / Q000382:microbiology; D015331:Cohort Studies; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology* / Q000401:mortality; D005260:Female; D005335:Fever of Unknown Origin / Q000188:drug therapy / Q000382:microbiology* / Q000401:mortality; D017052:Hospital Mortality; D006801:Humans; D007902:Length of Stay; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000382:microbiology; D011446:Prospective Studies; D013530:Surgical Wound Infection / Q000188:drug therapy / Q000382:microbiology* / Q000401:mortality; D013997:Time Factors; D016896:Treatment Outcome